Coronavirus (COVID-19)
- Ritonavir-Boosted Nirmatrelvir Prescribing Information
- Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir and Concomitant Medications
- The SARS-CoV-2 Monoclonal Antibody AZD3152 Potently Neutralizes Historical and Emerging Variants and is Being Developed for the Prevention and Treatment of COVID-19 in High-risk Individuals
- The Burden of COVID-19 in the Immunocompromised Patient: Implications for Vaccination and Needs for the Future
- Vaccines and therapeutics for immunocompromised patients with COVID-19
- Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study
- The Evolving Role of the Rheumatology Practitioner in the Care of Immunocompromised Patients in the COVID-19 Era
- Long COVID: major findings, mechanisms and recommendations
- Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients
- The COVID-19 Pandemic Rages on for People Who Are Immunocompromised
- CDC: COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised
- IDSA and CDC COVID-19 Real-Time Learning Network: Immunocompromised Populations
- Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
- NIH COVID-19 Treatment Guidelines: Therapeutic Management of Nonhospitalized Adults With COVID-19
- COVID-19 Drug Interactions
- Dexamethasone in Hospitalized Patients with Covid-19
- IDSA Guidelines on the Treatment and Management of Patients with COVID-19
- COVID-19 Real-Time Learning Network (IDSA)
- Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalized adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation
- Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
- Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
- NIH: Therapeutic Management of Hospitalized Adults With COVID-19
- NIH COVID-19 Treatment Guidelines
- FDA COVID-19 Emergency Use Authorizations: Drug and Biological Therapeutic Products
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 (ACTT-2)
- Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19 (COV-BARRIER)
- Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis
- Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY)
- CDC Coronavirus Disease 2019 (COVID-19) Resources
- WHO Resources: COVID-19 Pandemic
- Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
- Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
- JAMA Patient Page: Oral antiviral medications for COVID-19
- Molnupiravir EUA
- Nirmatrelvir EUA
Gram-negative Bacterial Infections
- Gram-negative Bacteria Infections in Healthcare Settings
- IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 1.0
- RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
- Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
- New Perspectives on Antimicrobial Agents: Cefiderocol
Cytomegalovirus (CMV)
- Letermovir for Primary and Secondary CMV Prevention: Real-world experience
- Letermovir for Secondary Prophylaxis of CMV Infection
- Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant
- Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation
- Cytomegalovirus (CMV) Infection
- About CMV for Patients
- Clinical manifestations, diagnosis, and management of CMV disease in kidney transplant recipients
- Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
- Maribavir for Treatment of CVM Infections Resistant or Refractory to Ganciclovir or Foscarnet in Hematopoietic SCT or SOT Recipients
Herpes Zoster
- Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines
- Efficacy and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis
- Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
- Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
- CDC: Shingles Vaccine Factsheet for Adult Patients
- CDC: Shingles Vaccine Factsheet for Health Care Professionals
HIV
- Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV
- INSTI Drug Interactions
- HIV and Drug-resistance Testing
- Evidence-based Interventions to Improve HIV Medication Adherence
- Optimizing Antiretroviral Therapy in the Setting of Virologic Suppression
- Adherence to the Continuum of Care
- Drug-Drug Interactions
- Drug Database: Cabotegravir
- Women with HIV
- Adverse Effects of Antiretroviral Therapy
- Considerations for Antiretroviral Therapy in the Older Patient
- Stanford University HIV Drug Resistance Database
- Understanding HIV Laboratory Tests – for Patients
- NNRTI Drug Interactions
- NRTI Drug Interactions
- PI Drug Interactions
- Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents- Tables
- What to Start: Selecting a First HIV Regimen
- ViiV, J&J’s Cabenuva gains FDA approval as long-acting regimen for HIV
PrEP
- Patient/Clinician Handout: PrEP 2-1-1
- HIV PrEP With FTC/TDF Among Cisgender Women
- Equity of Prep Uptake by Race, Ethnicity, Sex, and Region in the US in the First Decade of Prep
- Characteristics Associated with PrEP Discussion and Use Among Transgender Women Without HIV Infection – National HIV Behavioral Surveillance
- Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections
- Safety Review of TDF/FTC PrEP for Pregnant Women at Risk of HIV Infection
- On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
- PrEP Resources in all 50 States
- National Clinician Consultation Center for PrEP
- Preexposure Prophylaxis for the Prevention of HIV Infection of the United States – 2021 Update
- Quick Guide: 2021 PrEP Update
- Pre-Exposure Prophylaxis (PrEP)
- HIV Prevention Materials for Your Practice
- Let’s Stop HIV Together: HIV Prevention
- Drug information on cabotegravir
- Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women (HPTN 083)
- Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women: results from HPTN 084
Influenza
- A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017–18 influenza season – ScienceDirect
- Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing
- Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts
- Baloxavir Prescribing Information
- 2018 Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza
- Seasonal Influenza Vaccine Effectiveness Studies
- Influenza Antiviral Medications: Summary for Clinicians
- FDA-cleared Nucleic Acid Detection Based Tests for Influenza Viruses
- Information for Clinicians on Influenza Virus Testing
- What You Should Know About Influenza (Flu) Antiviral Drugs
- Diagnostic Accuracy of Novel and Traditional Rapid Tests for Influenza Infection Compared With Reverse Transcriptase Polymerase Chain Reaction
- Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents
- People at High Risk For Flu Complications
- Clinical Outcomes of Oseltamivir vs. Baloxavir in Patients Hospitalized with Influenza A
- Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children
- Early Treatment With Baloxavir Marboxil in High-Risk Adolescent and Adult Outpatients With Uncomplicated Influenza (CAPSTONE-2): A Randomised, Placebo-controlled, Phase 3 Trial
- Similarities and Differences between Flu and COVID-19
Invasive Fungal Infections
- CDC Fungal Diseases – Patient Information
- Information for Healthcare Professionals about Invasive Candidiasis
- Information for Healthcare Professionals about Mucormycosis
- Information for Healthcare Professionals about Aspergillosis
- Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
- Isavuconazonium sulfate Prescribing Information
- New Concepts in Diagnostics for Invasive Mycoses: Non-Culture-Based Methodologies
Molecular Diagnostics
- A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology
- Panels and Syndromic Testing in Clinical Microbiology
- Syndromic Panel-Based Testing in Clinical Microbiology
- New and novel rapid diagnostics that are impacting infection prevention and antimicrobial stewardship
- Advances in rapid diagnostics for bloodstream infections
- Diagnostic test accuracy of the BioFire® FilmArray® meningitis/encephalitis panel: a systematic review and meta-analysis
- Relationship of Multiplex Molecular Pneumonia Panel Results With Hospital Outcomes and Clinical Variables
- Enhanced Detection of Community-Acquired Pneumonia Pathogens With the BioFire® Pneumonia FilmArray® Panel
Pediatrics
- Recommendations for Prevention and Control of Influenza in Children, 2022–2023
- CDC Facts About Crypto and Swimming Pools – Patient Handout
- Cryptosporidiosis
- Giardiasis
- Swimming Pool Hygiene
- Facts About Crypto and Swimming Pools – Patient Handout
- Human Papillomavirus (HPV): The Need to Immunize – Patient Handout
Pneumococcal Disease
- Advisory Committee on Immunization Practices (ACIP): Pneumococcal Vaccine Recommendations
- Updated ACIP Recommendations and Evidence Review: Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children
- Updated ACIP Recommendations and Evidence Review: Use of PCV15 and PCV20 Among US Adults
- Immunize.org Ask the Experts: Pneumococcal Vaccines for Children and Adults
- Pneumococcal Vaccination
- ACIP: Clinical Considerations for Use of PCV15 in Children
- AAFP: Simplifying Pneumococcal Immunizations for Adults
- Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States
- Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults
- Association Between the Decline in Pneumococcal Disease in Unimmunized Adults and Vaccine-Derived Protection Against Colonization in Toddlers and Preschool-Aged Children
- Pneumococcal Conjugate Vaccine Breakthrough Infections: 2001-2016
- PneumoRecs VaxAdvisor Mobile App
- Racial Disparities in Adult Pneumococcal Vaccination
- Marked Reduction of Socioeconomic and Racial Disparities in Invasive Pneumococcal Disease Associated With Conjugate Pneumococcal Vaccines
- PCV15 Prescribing Information
- PCV20 Prescribing Information
Respiratory Syncytial Virus (RSV)
- RSV surges early in 2022, but appears to make early retreat
- Updated Guidance: Use of Palivizumab Prophylaxis to Prevent Hospitalization From Severe Respiratory Syncytial Virus Infection During the 2022-2023 RSV Season
- Multiple RSV vaccines in late-stage development show promise in older adults
- CYPRESS Phase 2b Data on the Efficacy and Immunogenicity of an Ad26.RSV.preF-based RSV Vaccine
- Why Making a Diagnosis of Respiratory Syncytial Virus Should Matter to Clinicians
- Severe Morbidity and Mortality Associated With Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults
- Incidence of Respiratory Syncytial Virus Infection Among Hospitalized Adults, 2017-2020
- A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults
- Respiratory Syncytial Virus in Older Adults: A Hidden Epidemic. A Report by the National Foundation for Infectious Diseases
- Respiratory Syncytial Virus (RSV)
- CDC Factsheet. RSV in Older Adults and Adults with Chronic Medical Conditions
- Advances in RSV Vaccine Research and Development – A Global Agenda
- Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study
- Respiratory Syncytial Virus Infection
- Respiratory Syncytial Virus in Older Adults: A Hidden Epidemic. A Report by the National Foundation for Infectious Disease